The Siren Song of Scale: Why Big Pharma's Mega-Mergers So Often Fall Flat

India's Silent Epidemic: A Global Pharma Giant Steps Up the Fight Against Obesity with a Local Powerhouse

The GLP-1 Gold Rush: Will Trump Rewrite the Rules for Eli Lilly and Novo Nordisk?

The Great Indian Weight Loss Gambit: A New Oral Frontier Arrives

The Bidding Blitz: Why Novo Nordisk's Loss to Pfizer Isn't Just About Money

The Billion-Dollar Battle for a Breakthrough: Pfizer's Big Bet on Oral Obesity Drugs

The Race for a Breakthrough: Pfizer's Bold Bet on Battling Obesity, Outmaneuvering Novo Nordisk

The Great Pharmaceutical Scramble: Pfizer Bags Metsea in High-Stakes Obesity Drug Duel

The Billion-Dollar Battle for the Future of Weight Loss: Pfizer Jumps into the Ring

The Weight of Ambition: Pfizer’s Bold Move into the Obesity Race

The Prize Fight for Progress: Pfizer Snags Metacrine in a High-Stakes Metabolic Drug Scramble

The $11.6 Billion Bet: Pfizer Jumps Headfirst into the Weight Loss Race

The Pharmaceutical Thunderdome: Pfizer's Bold Play in the Billion-Dollar Battle for Obesity Drugs

The Great Weight-Loss Gambit: Pfizer Jumps into the Billion-Dollar Battle for Obesity Treatment Supremacy

The Great GLP-1 Gold Rush: Pfizer Jumps into the Billion-Dollar Battle for Weight Loss Dominance

The Great Weigh-In: Pfizer's Bold Bet in the Billion-Dollar Battle for Obesity Drug Dominance

The Great Weight-Loss Race: Pfizer's Billion-Dollar Gambit to Conquer Obesity

The High-Stakes Game of Weight Loss: Pfizer's Gambit in the GLP-1 Gold Rush

The Price of Progress? Unpacking the Billion-Dollar Buzz Around America's New Weight-Loss Fixes

The Pharma Gambit: Why Pfizer Might Just Snatch Metsara from Novo's Grasp

The Watchdogs Are Barking: Why Metsera's Big Deal Just Hit a Snag

Unwavering Resolve: Novo Nordisk's Chief Eyes the Finish Line on Metsä Deal

The Billion-Dollar Beatdown: How Novo Nordisk Clinched Metsera in a High-Stakes Pharma Showdown

The GLP-1 Gambit: Pharma Giants, Trump, and the High Stakes of Drug Prices

The Great Negotiation: Big Pharma, Weight Loss, and the White House

The Weight of Expectation: FDA, Obesity Drugs, and the Uneasy Dance Between Speed and Safety

The Great GLP-1 Gambit: Navigating Novo Nordisk's Wild Ride

Caught in the Crossfire: Pfizer Accuses Novo Nordisk of Sabotaging a Critical Biotech Merger

The Billion-Dollar Standoff: Pfizer Takes On Novo Nordisk for a Slice of the Future

The Weight-Loss Gold Rush: Why All Eyes Are On Viking Therapeutics After a Hefty Biotech Deal

The Billion-Dollar Standoff: Pfizer Unleashes on Novo Nordisk in Metsera Bid Battle

The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night

The Ozempic Paradox: When a Brand's Triumph Threatens Its Very Name

Beyond the Scale: How Anti-Obesity Drugs Are Revolutionizing Heart Health

Biotech's Vanguard: Novo Nordisk, Omeros, and GSK Charting New Territories in Medical Innovation

Omeros Stock Skyrockets: Novo Nordisk Seals Massive $2.1 Billion Rare Disease Drug Deal

The Production Predicament: How Manufacturing Woes Threaten Novo Nordisk's Blockbuster Drugs

Healthcare Giants Soar: Novo Nordisk, Bristol Myers Squibb, and J&J Lead the Week's Breakthroughs

Novo Nordisk Shifts Focus: Why the Cell Therapy Unit is Closing Its Doors